BridgeBio Oncology Therapeutics
bbotx.com
Actively hiring
Precision Medicine
Health Care
Drug Discovery
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
3
Wellington Management, Aisling Capital
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Hacker News stories
1
best: 1 points
Backed byfrom the funds' portfolios and accelerator catalogs
Wellington Management 
Aisling Capital 
GV Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Precious MD is developing a companion diagnostic to identify the lung cancer patients who benefit from receiving EGFR inhibiting ...
Precision oncology, built for Latin America. Point-of-care software and a multimodal cancer atlas.
Pre-Amp is Amplitude Venture’s innovation engine for discovering, incubating, and funding innovation in precision medicine.
About UsGET TO KNOWOur Founders The medical potential of AI and metabolite Dr. Leila Pirhajico-founderOn Beyond Genome: Opportunities and…
StratifAI is a precision oncology company developing the next generation of biomarkers to advance cancer diagnostics.
Kynexis is leading the way in precision medicine, focusing on the treatment of cognitive impairment associated with schizophrenia (CIAS)…
Overview
Redefining what’s possible in precision oncology to treat RAS-dependent cancers. Inhibiting Active RAS. Going beyond current approaches.
News
BridgeBio Oncology Therapeutics (BBOT) Bets Big On A Narrower KRAS Playbook
On September 8, BridgeBio Oncology Therapeutics (NASDAQ:BBOT) released new clinical data for its lead KRASG12C inhibitor, BBO-8520, and used the moment to narrow its focus: the company is now prioritizing BBO-8520 paired with a checkpoint inhibitor in pre
Read more
Report
BridgeBio Oncology Therapeutics, Inc.: BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Continued to advance monotherapy and combination cohorts for all clinical programsInitiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO-11818
Read more
Report
BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment
Read more
Report
Is BridgeBio Oncology Therapeutics, Inc. (BBOT) Stock a Rising Oncology Opportunity With KRAS G12C Therapy Potential?
We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. BridgeBio Oncology Therapeutics, Inc. (NASDAQ:BBOT) is one of the most promising stocks on our list. TheFly reported on June 22 that Oppenheimer initiate
Read more
Report
Report
BBOT Archives
BBOT (BBOT) stock news, price prediction, earnings and analysis from 24/7 Wall St. BridgeBio Oncology Therapeutics, Inc. is an innovative clinical-stage…
Read more
Report
Show more news